blank image
PhotoBiotics banner image

Innovative Targeted Therapeutics from PhotoBiotics


Bespoke targeting agents for MRI imaging and cancer treatment. We call this OptiLink

About Us

PhotoBiotics Ltd is a multidisciplinary spin-out from Imperial College London UK which combines chemistry, photophysics, and biochemistry ... read more »

Technology / Pipeline

Optilink - Light activated moleculesOptiLink is a unique and simple conjugation platform for better drug delivery in imaging and therapy. It enables multiple loading of drug molecules and imaging agents onto specifically bio-engineered antibody fragments... read more »

OptiLink technology is currently being used with photosensitiser innovations to create ProstaLite, a promising novel targeted light activated therapy for prostate cancer.

As our pipeline evolves, OptiLink will deliver novel targeted 'see and treat' agents to improve efficacy and tolerability of treatment, significantly shorten tumour treatment times, and improve quality of life for patients... read more »

Latest News

PDT and Cancer treatment
PhotoBiotics announces the development of 3rd generation photosensitisers targeting lipid-rich organelles in tumours...




Copyright PhotoBiotics : All Rights Reserved
Department of Life Sciences
Faculty of Natural Sciences, Biochemistry Building
Imperial College London, Exhibition Rd
London,
SW7 2AZ, UK
Valid XHTML 1.0 Transitional
Web Design by Internetology